Castle Biosciences (NASDAQ: CSTL) CEO sells 4,172 shares via trusts
Castle Biosciences CEO Derek Maetzold sold a total of 4,172 shares of common stock at a weighted-average price of $25.098 per share on April 21, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. Concurrently, Maetzold exercised stock options to acquire 550 shares at $2.39 per share, selling a matching number of shares. After these transactions, Maetzold directly holds 21,479 shares, with additional indirect holdings through various family trusts.
APR 9·MarketBeat→
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 6,214 Shares of Stock
Castle Biosciences insider Derek Maetzold sold 6,214 shares of the company's stock on April 6th, reducing his stake by over 22%. The stock is currently trading below its 50-day and 200-day moving averages, with a market capitalization of $748.92 million. Despite the insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $47.57.
MAR 31·Investing.com→
Castle Biosciences CEO Maetzold sells shares worth $106,598
Castle Biosciences Inc (NASDAQ:CSTL) President and CEO Derek J. Maetzold sold 4,400 shares of common stock for $106,598 on March 26, 2026, under a pre-arranged trading plan. Despite the stock's recent decline and being undervalued according to InvestingPro, the company recently surpassed Q4 2025 earnings and revenue expectations. Analysts have maintained a Buy rating, citing strong revenue growth and positive data presented from its DecisionDx-Melanoma test.
